Categories: News

Vascular Perfusion Solutions Announces Collaboration with Wyss Institute at Harvard to Advance Biostasis Compounds for Organ Preservation

SAN ANTONIO, Nov. 26, 2025 /PRNewswire/ — Vascular Perfusion Solutions, Inc. (VPS) announced a collaboration with the Wyss Institute at Harvard University, the University of Colorado, and the University of Wyoming under the Advanced Research Projects Agency for Health (ARPA-H) Tissue Preservation under Stress (TiPS) project. The partnership aims to advance novel biostasis compounds to enhance organ preservation. As part of this collaboration, VPS will conduct translational testing of these compounds to develop an advanced perfusion solution designed to extend organ preservation time and increase donor organ utilization.

“Extending the safe preservation window is essential to improving access and equity in transplantation,” said Rafael J. Veraza, PhD, MPH, CEO and President of VPS, and Co-Investigator on the grant. “By working with the Wyss Institute and our academic partners, we aim to translate cutting-edge biostasis science into practical, scalable solutions.”

About VPS: Vascular Perfusion Solutions (VPS) is developing the VP.S ENCORE® platform, a simple and portable system designed to preserve donor hearts and other organs for extended durations. By enabling longer preservation times, VPS aims to increase organ utilization, reduce geographic limitations, and improve equity in organ allocation.

VP.S ENCORE® is an investigational device, currently in development and not yet approved for commercial use by the FDA.

Media Contact:
Rafael Veraza
210-977-0191
405502@email4pr.com 

View original content:https://www.prnewswire.com/news-releases/vascular-perfusion-solutions-announces-collaboration-with-wyss-institute-at-harvard-to-advance-biostasis-compounds-for-organ-preservation-302626174.html

SOURCE Vascular Perfusion Solutions, Inc.

Staff

Recent Posts

Atropos Health Expands Oncology Precision Medicine Capabilities with Publication of New AI Algorithms for Rare Disease and Integration of ASCO Guidelines

Atropos Health is integrating the American Society of Clinical Oncology® (ASCO®) Guidelines into their platform…

5 hours ago

USF and Old Dominion to Play in the 2025 StaffDNA Cure Bowl

PLANO, Texas, Dec. 5, 2025 /PRNewswire/ -- Teams playing in the StaffDNA® Cure Bowl were…

5 hours ago

The Dot Corp Expands Services With New Promotional Products & Apparel Division

IRVINE, Calif., Dec. 5, 2025 /PRNewswire/ -- The Dot Corp has expanded its services with…

5 hours ago

Vaniam Group Launches Predictive Pathways: A New Capability for Anticipating Market-Shaping Signals

CHICAGO, Dec. 5, 2025 /PRNewswire/ -- Vaniam Group™, a category leader redefining medical communications, announced…

5 hours ago

Biorep Technologies Announces First Successful Independent Research Use of the PRISM System in Islet Isolation

Results confirm reproducibility and research readiness for islet isolation of Biorep's next generation laboratory platform.MIAMI,…

5 hours ago